@article{Sarzi- Puttini_Torta_Marinangeli_Biasi_Spath_Buskila_Gracely_Giamberardino_Bazzichi_Cazzola_Di Franco_Stisi_Salaffi_Casale_Leardini_Gorla_Marsico_Carignola_Altomonte_Ceccherelli_Cassisi_Arioli_Alciati_Atzeni_2008, title={Fibromyalgia syndrome: the pharmacological treatment options}, volume={60}, url={https://www.reumatismo.org/reuma/article/view/reumatismo.2008.1s.50}, DOI={10.4081/reumatismo.2008.1s.50}, abstractNote={Fibromyalgia (FM), also known as fibromyalgia syndrome (FMS), is a frequently observed systemic disorder characterized by widespread musculoskeletal pain (1, 2). Its prevalence in the general population is 1-3%, and it is more common among females than males. The American College of Rheumatology (ACR) classification criteria defines it as widespread pain with patients endorsing at least 11 of 18 tender points as painful (3). Although its defining feature is chronic, widespread pain, FM patients may also have a number of other symptoms including sleep disturbance, fatigue, irritable bowel syndrome, headache and mood disorders (1)....}, number={s1}, journal={Reumatismo}, author={Sarzi- Puttini, P. and Torta, R. and Marinangeli, F. and Biasi, G. and Spath, M. and Buskila, D. and Gracely, R.H. and Giamberardino, M.A. and Bazzichi, L. and Cazzola, M. and Di Franco, M. and Stisi, S. and Salaffi, F. and Casale, R. and Leardini, G. and Gorla, R. and Marsico, A. and Carignola, R. and Altomonte, L. and Ceccherelli, F. and Cassisi, G. and Arioli, G. and Alciati, A. and Atzeni, F.}, year={2008}, month={Mar.}, pages={50–58} }